STOCK TITAN

Pyxis Oncology, Inc. - PYXS STOCK NEWS

Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.

Pyxis Oncology, Inc. (symbol: PYXS) is a clinical stage biotechnology company focused on the development of next-generation therapeutics designed to combat difficult-to-treat cancers. The company's mission is to enhance the body's immune response to cancer by targeting specific tumor micro-environments, employing cutting-edge antibody-drug conjugates (ADCs) and immuno-oncology (IO) strategies. Pyxis Oncology aims to improve the quality of life for cancer patients through innovative treatments that directly kill tumor cells and address the pathological factors that enable cancer's proliferation and immune evasion.

Pyxis Oncology is currently developing multiple therapeutic candidates, including PYX-201 and PYX-106, which are in Phase 1 clinical studies targeting a variety of solid tumors. These candidates are designed to be effective both as monotherapies and in combination with existing treatments, providing versatile approaches to cancer therapy. PYX-201 is being evaluated for its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced solid tumors. Similarly, PYX-106 is being assessed in a first-in-human, open-label, multicenter Phase 1 clinical study.

In addition to its robust pipeline, Pyxis Oncology is backed by substantial financial support from institutional investors such as Deep Track Capital, Ridgeback Capital Investments L.P., Blue Owl Healthcare Opportunities, Laurion Capital Management, and StemPoint Capital L.P. Recently, the company secured additional financing to further its research and development efforts, with Leerink Partners and LifeSci Capital serving as placement agents for the private placement.

Pyxis Oncology is committed to translating its preclinical findings into effective clinical treatments. The company has also actively participated in key industry conferences, such as the Society for Immunotherapy of Cancer (SITC) annual meeting, where its research on PYX-201, PYX-106, and other candidates was presented through posters and oral presentations.

Looking forward, Pyxis Oncology has outlined several anticipated milestones, including upcoming financial results for Q4 and the full year 2023, and further updates on their clinical programs. Investors and stakeholders can stay informed through regular updates and detailed news releases.

For more information, visit the Pyxis Oncology website or contact Pamela Connealy, CFO and COO, at ir@pyxisoncology.com.

Rhea-AI Summary
Pyxis Oncology (PYXS) provided a corporate update, reporting progress on PYX-201 and PYX-106 Phase 1 trials, completion of a $50 million private placement, and an expected cash runway into 2H 2026. PYX-201 has shown promising safety profiles with no significant toxicities, and PYX-106 is enrolling subjects for initial results anticipated in 2H 2024. Financially, Pyxis Oncology had $120.8 million in cash and equivalents as of December 31, 2023, with a decrease in research and development expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
-
Rhea-AI Summary
Pyxis Oncology, Inc. appoints Dr. Santhosh Palani, a seasoned leader with biopharma experience, to its board of directors. Dr. Palani's expertise will aid in the clinical development of their lead assets, including PYX-201, targeting difficult-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
management
-
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) to participate in a fireside chat at Leerink Partners Global Biopharma Conference. Dr. Lara S. Sullivan, President and CEO, will lead the discussion on March 13, 2024. Investors can access the webcast and presentation replay on Pyxis Oncology's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.63%
Tags
conferences
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) announces the presentation of new preclinical data on PYX-201, a tumor stroma-targeting ADC, at the 2024 AACR Annual Meeting. The data shows potent anti-tumor efficacy across various human cancers in PDX tumor models, with the target EDB+FN overexpressed in multiple solid tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences clinical trial
-
Rhea-AI Summary
Pyxis Oncology, Inc. announces a private placement of common stock and pre-funded warrants to raise capital for developing cancer therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.26%
Tags
none
-
Rhea-AI Summary
Pyxis Oncology, Inc. (Nasdaq: PYXS) reported the approval of a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, under the Pyxis Oncology, Inc. 2022 Inducement Plan. The option to purchase 443,514 shares will vest over four years, with an additional 110,878 shares vesting upon achievement of certain clinical milestones related to data disclosure for PYX-201. The stock options have a ten-year term and an exercise price of $1.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.44%
Tags
none
Rhea-AI Summary
1910 Genetics (Ticker: 1910) appoints Dr. Shaan C. Gandhi, MD, DPhil, as independent board director, bringing clinical, strategic, and financial leadership. Dr. Gandhi, VP and Head of Strategic Partnerships for Pfizer Ignite, will provide critical clinical perspective and extensive background in biotechnology investing and strategic collaboration to guide the company's trajectory for continued success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
management
-
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) appoints Dr. Ken Kobayashi as Chief Medical Officer, bringing extensive experience in oncology drug development and regulatory affairs. Dr. Kobayashi will lead clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology’s clinical pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
management
-
Rhea-AI Summary
Pyxis Oncology, Inc. (Nasdaq: PYXS) extends cash runway to 2026, reports $134.4 million in cash, and announces Phase 1 trial progress for PYX-201 and PYX-106 programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
Rhea-AI Summary
Pyxis Oncology announces acceptance of four abstracts for poster presentation at SITC 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none

FAQ

What is the current stock price of Pyxis Oncology (PYXS)?

The current stock price of Pyxis Oncology (PYXS) is $3.93 as of November 5, 2024.

What is the market cap of Pyxis Oncology (PYXS)?

The market cap of Pyxis Oncology (PYXS) is approximately 228.8M.

What is Pyxis Oncology, Inc.?

Pyxis Oncology is a clinical stage biotech company developing next-generation cancer therapeutics.

What are the company's core products?

Pyxis Oncology's core products include PYX-201 and PYX-106, which target advanced solid tumors.

What is the focus of Pyxis Oncology's research?

The company focuses on developing treatments that enhance the immune response and directly kill tumor cells.

Who are some of Pyxis Oncology's investors?

Investors include Deep Track Capital, Ridgeback Capital Investments L.P., Blue Owl Healthcare Opportunities, Laurion Capital Management, and StemPoint Capital L.P.

What recent achievements has Pyxis Oncology announced?

The company has secured additional financing and presented at major industry conferences such as SITC.

What is the purpose of PYX-201?

PYX-201 is designed to target advanced solid tumors by evaluating its safety, tolerability, and efficacy in Phase 1 clinical studies.

How does PYX-106 differ from PYX-201?

PYX-106 is an anti-Siglec-15 antibody targeting advanced solid tumors through similar Phase 1 studies.

What future milestones has Pyxis Oncology outlined?

Upcoming milestones include releasing full year and Q4 2023 financial results and further clinical updates.

How can I contact Pyxis Oncology?

For inquiries, you can contact Pamela Connealy, CFO and COO, at ir@pyxisoncology.com.

Where can I find more information about Pyxis Oncology’s presentations?

Presentation details and posters are available on the Pyxis Oncology website following conference events.

Pyxis Oncology, Inc.

Nasdaq:PYXS

PYXS Rankings

PYXS Stock Data

228.78M
59.42M
19.94%
55.34%
8.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON